Literature DB >> 22684027

Pretreatment with IFN-α increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia.

Yin Xiao, Hui-hua Hu, Hong-xiang Wang, Xiao-jian Zhu, Ping Zou, Zhi-chao Chen, Zhao-dong Zhong, Wei-ming Li, Yong You.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22684027      PMCID： PMC4011157          DOI： 10.1038/aps.2012.43

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN： 1671-4083            Impact factor:   6.150


× No keyword cloud information.
  7 in total

1.  Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

Authors:  Susan Branford; Zbigniew Rudzki; Sonya Walsh; Ian Parkinson; Andrew Grigg; Jeff Szer; Kerry Taylor; Richard Herrmann; John F Seymour; Chris Arthur; David Joske; Kevin Lynch; Tim Hughes
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

Review 2.  Interferon alpha for treatment of chronic myeloid leukemia.

Authors:  Bengt Simonsson; Henrik Hjorth-Hansen; Ole Weis Bjerrum; Kimmo Porkka
Journal:  Curr Drug Targets       Date:  2011-03-01       Impact factor: 3.465

3.  Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo.

Authors:  Amitava Sengupta; Jorden Arnett; Susan Dunn; David A Williams; Jose A Cancelas
Journal:  Blood       Date:  2010-04-20       Impact factor: 22.113

Review 4.  The renaissance of interferon therapy for the treatment of myeloid malignancies.

Authors:  Jean-Jacques Kiladjian; Ruben A Mesa; Ronald Hoffman
Journal:  Blood       Date:  2011-03-09       Impact factor: 22.113

Review 5.  Chronic myeloid leukemia.

Authors:  Junia V Melo; Timothy P Hughes; Jane F Apperley
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2003

Review 6.  The role of interferon-alpha in the treatment of chronic myeloid leukemia.

Authors:  Lisa A Kujawski; Moshe Talpaz
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-20       Impact factor: 7.638

7.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.